Oncotelic Therapeutics' Nanomedicine Platform Shows Promise in Reducing Drug Side Effects
TL;DR
Oncotelic Therapeutics' Deciparticle platform offers a competitive edge by enabling intravenous delivery of hydrophobic drugs, potentially improving efficacy and reducing side effects compared to oral dosing.
The Deciparticle platform works by formulating hydrophobic drugs into uniform nanoparticles for intravenous use, with preclinical data showing reduced gastrointestinal accumulation for Everolimus.
This nanomedicine technology could make cancer treatments more effective and tolerable, improving patient outcomes and quality of life in immunology and oncology.
Oncotelic's platform can package water-resistant drugs like macrolide mTOR inhibitors into tiny nanoparticles, a breakthrough that transforms how challenging medications are delivered intravenously.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics Inc. (OTLC) has unveiled new data showing its Deciparticle platform can significantly reduce gastrointestinal drug accumulation for cancer treatments, potentially addressing a major side effect issue in oncology care. The company's intravenous formulation of Everolimus (marketed as Afinitor) demonstrated a 67-fold reduction in gastrointestinal accumulation compared to oral dosing in preclinical studies.
The Deciparticle platform reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles. This technology represents a significant advancement in drug delivery systems, particularly for water-resistant medications that have traditionally been difficult to administer intravenously. The platform's ability to create smaller, uniform nanoparticles enables more effective and safe intravenous use of these important therapeutic agents.
New data presented at the 2025 San Antonio Breast Cancer Symposium highlighted the platform's broad compatibility across different therapeutic categories. All five main macrolide mTOR inhibitors—including temsirolimus, sirolimus, ridaforolimus, Everolimus, and umirolimus—formed stable, monodisperse particles through this technology. The platform also successfully formulated tacrolimus, another key therapeutic agent, into stable nanoparticles suitable for intravenous administration.
This development is particularly important because gastrointestinal side effects represent a significant challenge in cancer treatment, often limiting patient tolerance and treatment adherence. By reducing drug accumulation in the gastrointestinal tract by up to 67-fold, the Deciparticle platform could potentially minimize these debilitating side effects while maintaining therapeutic efficacy. The technology's modular, cGMP-ready engineering supports rapid development and scalability, positioning Oncotelic Therapeutics as an emerging player in next-generation drug delivery systems.
The company's clinical-stage nanomedicine, Sapu Nano, forms the foundation of this expanding immunology and oncology pipeline. The platform's ability to transform water-resistant drugs into intravenous formulations addresses a longstanding challenge in pharmaceutical development. As noted in the company's presentation materials available at https://ibn.fm/LxQ7N, this technology could transform treatment paradigms for various cancers and immunological conditions by enabling more targeted drug delivery with reduced systemic side effects.
For investors and industry observers following these developments, the latest news and updates relating to OTLC remain available through the company's communications channels. The broader implications of this technology extend beyond individual drug formulations to potentially reshape how hydrophobic medications are developed and administered across multiple therapeutic areas, offering hope for improved patient outcomes through more precise drug delivery mechanisms.
Curated from InvestorBrandNetwork (IBN)
